These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 25312733)

  • 1. Adverse effects of statins - myths and reality.
    Šimić I; Reiner Ž
    Curr Pharm Des; 2015; 21(9):1220-6. PubMed ID: 25312733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
    Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
    Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromuscular complications of statins.
    Ahn SC
    Phys Med Rehabil Clin N Am; 2008 Feb; 19(1):47-59, vi. PubMed ID: 18194749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
    Evans M; Rees A
    Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety considerations for statins.
    Bolego C; Baetta R; Bellosta S; Corsini A; Paoletti R
    Curr Opin Lipidol; 2002 Dec; 13(6):637-44. PubMed ID: 12441888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.
    Newman CB; Preiss D; Tobert JA; Jacobson TA; Page RL; Goldstein LB; Chin C; Tannock LR; Miller M; Raghuveer G; Duell PB; Brinton EA; Pollak A; Braun LT; Welty FK;
    Arterioscler Thromb Vasc Biol; 2019 Feb; 39(2):e38-e81. PubMed ID: 30580575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials.
    Alsheikh-Ali AA; Karas RH
    Curr Atheroscler Rep; 2009 Mar; 11(2):100-4. PubMed ID: 19228482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse effects of statins - mechanisms and consequences.
    Bełtowski J; Wójcicka G; Jamroz-Wiśniewska A
    Curr Drug Saf; 2009 Sep; 4(3):209-28. PubMed ID: 19534648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-cardiovascular effects associated with statins.
    Desai CS; Martin SS; Blumenthal RS
    BMJ; 2014 Jul; 349():g3743. PubMed ID: 25035309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The myopathy of statins.
    Smogorzewski M
    J Ren Nutr; 2005 Jan; 15(1):87-93. PubMed ID: 15648014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Statins and Nonstatins for Treatment of Dyslipidemia.
    Newman CB
    Endocrinol Metab Clin North Am; 2022 Sep; 51(3):655-679. PubMed ID: 35963634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are statins really wonder drugs?
    Grover HS; Luthra S; Maroo S
    J Formos Med Assoc; 2014 Dec; 113(12):892-8. PubMed ID: 24231094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Who should receive a statin these days? Lessons from recent clinical trials.
    Shepherd J
    J Intern Med; 2006 Oct; 260(4):305-19. PubMed ID: 16961668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adverse effects of statins].
    Andréjak M; Gras V; Massy ZA; Caron J
    Therapie; 2003; 58(1):77-83. PubMed ID: 12822204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of statins in clinical practice.
    Armitage J
    Lancet; 2007 Nov; 370(9601):1781-90. PubMed ID: 17559928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Muscle-related adverse effects of statins].
    Pohjola-Sintonen S; Julkunen H
    Duodecim; 2014; 130(16):1622-7. PubMed ID: 25269368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.